Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study

被引：17
|
作者：
Stamatoullas, Aspasia [1 ]
Ghesquieres, Herv [2 ]
Filliatre, Lauriane Clement [3 ]
Quittet, Philippe [4 ]
Morschhauser, Franck [5 ]
Ribrag, Vincent [6 ]
Edeline, Veronique [7 ]
Brice, Pauline [8 ]
机构：
[1] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[2] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France
[3] CHRU, Vandoeuvre Les Nancy, France
[4] CHU St Eloi, Dept Hematol, Montpellier, France
[5] Hop Claude Huriez, CHRU Lille, Lille, France
[6] Gustave Roussy, Villejuif, France
[7] Hop Rene Huguenin, Inst Curie, Serv Med Nucl, St Cloud, France
[8] Hop St Louis, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123925
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
132
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Maerevoet, Marie
    Meuleman, Nathalie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S250 - S250
  • [42] Sequential Brentuximab Vedotin Before and After Adriamycin, Vinblastine, and Dacarbazine for Older Patients With Untreated Classical Hodgkin Lymphoma: Final Results From a Multicenter Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 15 - 17
  • [43] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study
    Fanale, M. A.
    Kline, J.
    Chen, R.
    Ribrag, V.
    Salles, G.
    Matsumura, I.
    Zhu, Y.
    Ricart, A. D.
    Balakumaran, A.
    Zinzani, P. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Meuleman, Nathalie
    Bron, Dominique
    Maerevoet, Marie
    BLOOD, 2020, 136
  • [45] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [46] Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma
    Colunga-Pedraza, Panelperla R. R.
    Ulises Coronado-Alejandro, Edgar
    De La Garza, Fernando
    Gomez Gomez, Eliezer Tomas
    Gomez-De Leon, Andres
    Colunga Pedraza, Julia Esther
    Homero Gutierrez-Aguirre, Cesar
    Cantu Rodriguez, Olga Graciela
    Gomez-Almaguer, David
    BLOOD, 2021, 138
  • [47] Efficacy of Brentuximab Vedotin Plus Conventional Chemotherapy Regimens as Pre-Autologous Stem Cell Transplantation Re-Induction Salvage Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma
    Ridova, Nevenka
    Ivanovski, Martin
    Trajkova, Sanja
    Pivkova-Veljanovska, Aleksandra
    Chadievski, Lazar
    Dukovski, Dushko
    Popova-Labachevska, Marija
    Krstevska-Balkanov, Svetlana
    Stojanoski, Zlate
    Stojanovska-Jakimovska, Simona
    Cvetanoski, Milche
    Milovska, Dijana
    Grivchevska, Milena
    Kochoski, Bozidar
    Kostojchinoska, Viktorija
    Jakjimovski, Mario
    Panovska-Stavridis, Irina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S346 - S346
  • [48] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    Pinczes, Laszlo Imre
    Szabo, Roxana
    Illes, Arpad
    Foldeak, Dora
    Piukovics, Klara
    Szomor, Arpad
    Gopcsa, Laszlo
    Miltenyi, Zsofia
    ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2385 - 2392
  • [49] A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Armand, Philippe
    Rogula, Basia
    Johnston, Karissa
    Peterson, Derek
    Connors, Joseph M.
    Lozano-Ortega, Greta
    BLOOD, 2019, 134
  • [50] Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
    Marouf, Amira
    Cottereau, Anne Segolene
    Kanoun, Salim
    Deschamps, Paul
    Meignan, Michel
    Franchi, Patricia
    Sibon, David
    Antoine, Clara
    Gastinne, Thomas
    Borel, Cecile
    Hammoud, Mohammad
    Sicard, Guillaume
    Gille, Romane
    Cavalieri, Doriane
    Stamatoullas, Aspasia
    Filliatre-Clement, Lauriane
    Lazarovici, Julien
    Chauchet, Adrien
    Fornecker, Luc-Matthieu
    Amorin, Sandy
    Rocquet, Mathieu
    Raus, Nicole
    Burroni, Barbara
    Rubio, Marie Therese
    Bouscary, Didier
    Quittet, Philippe
    Casasnovas, Rene Olivier
    Brice, Pauline
    Ghesquieres, Herve
    Tamburini, Jerome
    Deau, Benedicte
    HAEMATOLOGICA, 2022, 107 (07) : 1681 - 1686
12345